Cytosorbents (CTSO) Prelim. Q3 Revenue Misses Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
CytoSorbents (CTSO) PT Lowered to $10 at Cowen, Keeps 'Outperform'
October 13, 2021 5:50 AM EDTCowen analyst Joshua Jennings lowered the price target on CytoSorbents (NASDAQ: CTSO) to $10.00 (from $14.00) while maintaining an Outperform rating following results and FDA approval of the IDE for DrugSorb's U.S. trial.
The analyst commented, "CTSO reported preliminary 3Q revenue of $9.7M,... More
